Navigation LinksTop Biology NewsTop Medical NewsTop Biology TechnologyTop Medical Technology


ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354

5/13/2008
Drug Represents Potential New Approach for the Treatment of Inflammatory Disease Milestone Triggers $10 Million Payment from Partner GlaxoSmithKline MOUNTAIN VIEW, Calif., May 13 /- ChemoCentryx, Inc., todayannounced the initiation of a Phase I clinical trial of CCX354, anorally-available, novel small molecule compound designed to specificallyt... [Comments]

NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.

5/13/2008
SOPHIA ANTIPOLIS, France, May 13 /- NicOx S.A.(Eurolist: COX) today announced that Merck & Co., Inc. has initiated thefirst in a series of planned clinical studies, in mild to moderatehypertensive patients, under the companies' collaborative agreement todevelop new nitric oxide-donating antihypertensive agents using NicOx'proprietary technology. Three drug candida... [Comments]

Ceremed's OSTENE(R) Improves Bone Fusion and Healing After Surgery, New Study Shows

5/13/2008
LOS ANGELES, May 13 /- New soluble polymer materialdesigned to stop bone bleeding in surgery improves bone fusion and healing,according to a new animal study just published in the Annals of ThoracicSurgery (ATS). The findings come on the heels of recently publishedresearch showing that the use of the new polymer may lower the risk ofsurgical infections. Researchers from t... [Comments]

Napo Presents at ISPOR Meeting in Toronto

5/12/2008
SOUTH SAN FRANCISCO, Calif., May 12 /- NapoPharmaceuticals, Inc., (LSE: NAPL and NAPU), announces that it presented aposter in collaboration with QualityMetric, Inc. describing the developmentof a patient reported outcomes questionnaire focused on the Health-RelatedQuality of Life (HR-QoL) aspects of chronic diarrhea in persons living withHIV/AIDS at the 13th Inte... [Comments]

Cardinal Health Completes Enturia Acquisition

5/12/2008
ChloraPrep(R) Products Expand Infection Prevention Business DUBLIN, Ohio, May 12 /- Cardinal Health, aglobal provider of products and services that improve the safety andproductivity of health care, today announced it has completed theacquisition of assets of privately held Enturia, Inc., the manufacturer ofinfection prevention products sold under the ChloraP... [Comments]

Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation

5/12/2008
- Intercell AG ('Intercell') to acquire Iomai Corporation ('Iomai') in a fully recommended share/cash transaction for USD 6.60 per share of Iomai's common stock representing a fully diluted equity value of Iomai of approximately USD 189 million (EUR 122 million). Acquisition to be accomplished through stock-for-stock exchange for approximately 41 percent of Iomai's current shares outsta... [Comments]

Prism Glasses Expand the View for Patients with Hemianopia

5/12/2008
Schepens study opens way for high-power permanent version of the glasses and larger new study BOSTON, May 12 /- Innovative prism glasses cansignificantly improve the vision and the daily lives of patients withhemianopia, a condition that blinds half the visual field in both eyes. Theperipheral prism glasses, which were invented by Dr. Eli Peli, a Seni... [Comments]

Lupus Under the Spotlight: U.S. Congress Shows Support for Women's Health Issues

5/12/2008
NEW YORK, May 12 -- The Alliance for LupusResearch (ALR) commends the Senate on its passage of a resolutionsupporting the goals and ideals of National Women's Health Week that beginsannually on Mother's Day. The resolution, introduced by Senators RussFeingold (D-WI) and Olympia Snowe (R-ME) calls on all Americans to take theweek of May 11th - May 17th as an oppor... [Comments]

GeoVax Secures $10 Million Financing Commitment

5/12/2008
ATLANTA, May 12 /- GeoVax Labs, Inc. (OTCBulletin Board: GOVX), an Atlanta- based HIV/AIDS vaccine developmentcompany, announced today that it has entered into a $10 million commonstock purchase agreement with Fusion Capital Fund II, LLC, a Chicago-basedinstitutional investor. The Company may sell up to $10 million of its common stock to FusionCapital from time... [Comments]

St. Jude Study Shows How T Cell's Machinery Dials Down Autoimmunity

5/12/2008
Immune cells adjust their function like a radio dial, not an on/offlight switch; a discovery that hints at how autoimmune disease may developlate in life MEMPHIS, Tenn., May 12 -- A St. Jude Children'sResearch Hospital study shows that T cells, the body's master immuneregulators, do not use simple on/off switches to govern the cellularmachinery that regulates... [Comments]

[next]
(Date:5/13/2008)... HARBIN, China, May 13 /Xinhua-PRNewswire-FirstCa...oard: CSKI), a manufacturer, marketer and,distribu...oducts in China,today announced that it will cond... May 15, 2008 to discuss its first quarter 2008 fi...man, CEO and Director of China Sky One,Medical, In...
(Date:5/13/2008)...ildbearing had no such benefit if baby was bottle-...13 (HealthDay News) -- Women who breast feed for m...arthritis (RA) by half, according to a new Swedish...g children but not breast-feeding offered women no...contraceptives also failed to reduce the risk of R...
(Date:5/13/2008)...NEW YORK (May 13, 2008) -- Promising results from ...ell Medical Center physician-scientists show that ... the progression of Batten disease, or Late Infant..., genetic, degenerative neurological disorder that... to 12. , The clinical trial found that the pro...
(Date:5/13/2008)... SALT LAKE CITY, May 13 /PRNewswire/ -- Paramed S...ent of their marine-grade Mobility Offers,Versatil...chair to oil and,gas platform operators in the Gul...platforms will enable the safe and timely evacuati...atform., Paramed developed the dual-track MOV in ...
Breaking Medicine News(10 mins):Health News:China Sky One Medical, Inc. Announces Conference Call to Discuss First Quarter 2008 Results 2Health News:Breast-feeding Might Shield Women From Rheumatoid Arthritis 2Health News:NYP/Weill Cornell gene therapy clinical trial yields promising results for Batten disease 2
... tissue abnormalities, or lesions, that typically ...nfected with multiple genotypes// of the human pap...ing to a study published in the July issue of Canc...ion. Although doctors have known that the cervica...
...ter is among 10 institutions selected to oversee i...ving interventions for critical trauma// and sudde...th has joined with other U.S. and Canadian agencie...on Outcomes Consortium (ROC) and establish federal...
...ttle super bugs, including MRSA, has found its way...d the news as Tygacil, is one of the few new antib...rs. Micro organisms have undergone mutations that...sistance to the existing antibiotics, leading to w...
...sleep would probably help the human brain to enhan...arned facts.// It was reported that previous stud...declarative memories, like the steps of learning t... It was explained that the new experiment focuses ...
Other Medicine News:Health News:Higher Risk for Cervical Cancer Seen Among Women Infected with Multiple HPV Types 2Health News:Higher Risk for Cervical Cancer Seen Among Women Infected with Multiple HPV Types 3Health News:Medical Center to Test Methods of Improving Cardiac Arrest, Trauma Survival 2Health News:New Drugs To Combat Mutant Bugs 2Health News:Sleep Essential For A Strong Memory 2
...sists of a sterile Hemostatic Dressing supplied to...,Both devices work together to promote dual-action...cal hemostasis by facilitating clotting at the ski...tem provides external compression to facilitate cl...
The ALLEGRO Analyzer has been specifically designed to deliver wavefront data needed to perform safe and successful wavefront guided laser vision correction. All components such as the user interface
Absolute precision demands absolute knowledge. Access it with the Bausch & Lomb Zyoptix Diagnostic Workstation, uniting two trusted technologies: Zywave II Wavefront Aberrometer and Orbscan IIz Anter
ZYMAR™ ophthalmic solution is an anti-infective prescription eye drop that your doctor may instruct you to use if you have an eye infection caused by bacteria. Bacterial conjunctivitis is the e
Medicine Products:
(Date:5/12/2008)... their function like a radio dial, not an on/off,l...une disease may develop,late in life, MEMPHIS, ...e Children,s,Research Hospital study shows that T ... use simple on/off switches to govern the cellular...nction. Rather, they,possess sophisticated molecul...
(Date:5/12/2008)... 12 /- Arbios Systems, Inc....he Company has received,approval from the U.S. Foo...ional Device Exemption ("IDE") to begin the pivota...real (outside the body) liver assist,device for bl... from,chronic liver disease., "We are pleased to ...
(Date:5/12/2008)...rt 3 Demonstrated Improvement in T-Cell Responses ...al of HspE7, SAN DIEGO, May 12 /PRNewswire-FirstC...: NVN) today announced positive immunological data...ical trial of its lead product,candidate, HspE7, i..., or,CIN, a precursor to cervical cancer. HPV 16 E...
(Date:5/9/2008).../PRNewswire-USNewswire/ -- Many strong acting pain...an include nausea and,vomiting with short-term use...symptoms can lead patients to discontinue treatmen...ent for physicians. The novel investigational,medi...ic, provided pain,relief for patients with fewer g...
Breaking Medicine Technology:St. Jude Study Shows How T Cell's Machinery Dials Down Autoimmunity 2St. Jude Study Shows How T Cell's Machinery Dials Down Autoimmunity 3St. Jude Study Shows How T Cell's Machinery Dials Down Autoimmunity 4Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Assist Device 2Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Assist Device 3Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Assist Device 4Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Assist Device 5Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 2Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 3Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 4Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 5Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 6New Study Suggests Tapentadol IR for Acute Pain Is Associated With Improved Gastrointestinal Tolerability Compared to Oxycodone IR 2New Study Suggests Tapentadol IR for Acute Pain Is Associated With Improved Gastrointestinal Tolerability Compared to Oxycodone IR 3New Study Suggests Tapentadol IR for Acute Pain Is Associated With Improved Gastrointestinal Tolerability Compared to Oxycodone IR 4Registry unveils real world data on novel excel stent 15505 1Registry unveils real world data on novel excel stent 15505 2Study finds support for PCI in unprotected left main disease 15501 1Study finds support for PCI in unprotected left main disease 15501 2Study finds support for PCI in unprotected left main disease 15501 3Response Biomedical Corporation Reports 2007 Financial Results 15498 1Response Biomedical Corporation Reports 2007 Financial Results 15498 2Response Biomedical Corporation Reports 2007 Financial Results 15498 3Response Biomedical Corporation Reports 2007 Financial Results 15498 4Response Biomedical Corporation Reports 2007 Financial Results 15498 5China Medicine Corporation to Present at Brean Murray Carret 26 Co Mainland China Investor Tour 15494 1China Medicine Corporation to Present at Brean Murray Carret 26 Co Mainland China Investor Tour 15494 2